SCHEMBL5063267

SCHEMBL5063267

O=C(O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 19/20 0.84
IKBKE Q14164 1/20 0.66
NEK2 P51955 4/20 0.59
CSF1R P07333 2/20 0.59
PIM1 P11309 2/20 0.59
KDR P35968 2/20 0.59
LIMK1 P53667 2/20 0.59
STK3 Q13188 2/20 0.59
DYRK1A Q13627 2/20 0.59
PKN2 Q16513 2/20 0.59
HIPK4 Q8NE63 2/20 0.59
BRSK1 Q8TDC3 2/20 0.59
AURKB Q96GD4 2/20 0.59
PLK3 Q9H4B4 2/20 0.59
CLK4 Q9HAZ1 2/20 0.59
MAP4K5 Q9Y4K4 2/20 0.59
MAP4K4 O95819 1/20 0.59
CAMK2B Q13554 1/20 0.59
CAMK2G Q13555 1/20 0.59
CAMK2D Q13557 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037261 0.91 PLK1 (1.00) PLK1IKBKENEK2CSF1RPIM1
SCHEMBL5063400 0.89 PLK1 (0.77) PLK1IKBKENEK2CSF1RPIM1
SCHEMBL3619763 0.88 PLK1 (0.72) PLK1IKBKENEK2CSF1RPIM1
SCHEMBL5062604 0.86 PLK1 (0.83) PLK1NEK2CSF1RPIM1KDR
SCHEMBL3616731 0.86 PLK1 (0.71) PLK1IKBKENEK2CSF1RPIM1
SCHEMBL3602464 0.85 PLK1 (0.70) PLK1IKBKENEK2CSF1RPIM1
SCHEMBL5062537 0.84 PLK1 (0.61) PLK1IKBKENEK2CSF1RPIM1
SCHEMBL3597838 0.84 PLK1 (0.71) PLK1NEK2CSF1RPIM1KDR
SCHEMBL5062189 0.83 PLK1 (1.00) PLK1NEK2CSF1RPIM1KDR
SCHEMBL5062311 0.83 PLK1 (1.00) PLK1NEK2CSF1RPIM1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269298-A1 Benzimidazol-1-YL-thiophene compounds for the treatment of cancer ANDREWS CLARENCE W 2008-10-30 US disclosed
US-20060074119-A1 Thiophene compounds SMITHKLINE BEECHAM CORPORATION 2006-04-06 US disclosed
EP-1546137-A1 BENZIMIDAZOL-1-YL-THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER SmithKline Beecham Corporation (US) 2005-06-29 EP disclosed
WO-2004014899-A1 THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074119-A1 Thiophene compounds TPMT, ABCB1, CYP3A5 PLK1 2123/4885IKBKE 3524/4885NEK2 4031/4885
US-20080269298-A1 Benzimidazol-1-YL-thiophene compounds for the treatment of cancer ABCB1, TP53, CCNI PLK1 130/4885IKBKE 609/4885NEK2 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.